Pazopanib works against the management of advanced neuroendocrine tumors (NETs) even after a failure of previous treatments, according to the PAZONET study published online ahead of print in the journal Annals of Oncology.

The Spanish Task Force Group for NETs (GETNE) conducted a multicenter, open-label, phase 2 trial and assigned all 44 patients to receive pazopanib monotherapy. 

The primary endpoint was clinical benefit rate (CBR) at 6 months, with traditional correlation of radiological response, progression-free survival (PFS) with circulating tumor cell (CTC) and tissue biomarkers, as the secondary endpoints.

Continue Reading

Results showed that there was a variance in CBR according to prior therapies: multitarget inhibitors (73%), mTOR inhibitors (60%), and both agents (25%).

Researchers found that the median PFS was 9.5 months (95% CI: 4.8, 14.1) and lower baseline circulating CTC count had no significant increase in PFS with 9.1 months compared with 5.8 months (P=0.22).

RELATED: Stereotactic Body Radiotherapy Using Fiducial Implants for Pancreatic Cancer

However, patients with VEGFR3rs307821 (HR=12.3; 95% CI: 1.09, 139.2; P=0.042) and rs307826 (HR= 6.9; 95% CI: 0.96, 49.9; P=0.055) polymorphisms wereshown to have reduced survival.

The study demonstrates that pazopanib shows activity among patients who previously failed treatment against NETs. Additional studies are warranted to investigate CTCs, soluble-s VEFGR-2 and VEGFR3 gene polymorphisms in NETs, as they wereshown to be potential biomarkers for pazopanib targeted therapy.


  1. Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv252.